基质金属蛋白酶家族在恶性肿瘤中的相关表达及其临床特征
Expression and Clinical Characteristics of Matrix Metalloproteinases in Malignant Tu-mors
摘要: 基质金属蛋白酶(matrix metalloproteinases)是一组锌依赖性的酶家族，在调节人体生理过程和病理过程尤其恶性肿瘤中的地位日渐显著。经研究表明，降解细胞外基质、调节基因多态性、促进上皮间质转化、诱导黏附分子表达等是MMPs参与肿瘤细胞侵袭和转移的具体过程。同时，MMPs在作为肿瘤诊断标志物、癌症预后、药物靶点等方面为临床提供了一定依据。在本篇综述中，阐述了MMPs在恶性肿瘤中的相关表达、对肿瘤细胞的作用特点以及关于临床生存、预后等情况。在本篇综述中，阐述了MMPs在恶性肿瘤中的相关表达、对肿瘤细胞的作用特点以及关于临床生存、预后等情况。
Abstract: Matrix metalloproteinases are a family of zinc-dependent enzymes, which play an increasingly prominent role in regulating human physiological and pathological processes, especially in malig-nant tumors. Studies have shown that MMPs are involved in the specific processes of tumor cell in-vasion and metastasis, such as degradation of extracellular matrix, regulation of gene polymor-phism, promotion of epithelial mesenchymal transformation, and induction of adhesion molecule expression. At the same time, MMPs as tumors diagnostic markers, cancer prognosis, drug targets and other aspects provide a certain basis for clinical. In this review, the relevant expression of MMPs in malignant tumors, the characteristics of its effects on tumors cell, as well as its clinical sur-vival and prognosis were described.
文章引用：李萌, 王淼舟. 基质金属蛋白酶家族在恶性肿瘤中的相关表达及其临床特征[J]. 临床医学进展, 2022, 12(5): 4355-4360. https://doi.org/10.12677/ACM.2022.125631

参考文献

[1] Egeblad, M. and Werb, Z. (2002) New Functions for the Matrix Metalloproteinases in Cancer Progression. Nature Re-views Cancer, 2, 161-174. [Google Scholar] [CrossRef] [PubMed]
[2] Wilson, C.L., Heppner, K.J., Labosky, P.A., Hogan, B.L. and Matrisian, LM. (1997) Intestinal Tumorigenesis Is Suppressed in Mice Lacking the Metalloproteinase Matri-lysin. Proceedings of the National Academy of Sciences of the United States of America, 94, 1402-1407. [Google Scholar] [CrossRef] [PubMed]
[3] Porte, H., Chastre, E., Prevot, S., Nordlinger, B., Empereur, S., Basset, P., et al. (1995) Neoplastic Progression of Human Colorectal Cancer Is Associated with Overexpression of the Strome-lysin-3 and BM-40/SPARC Genes. International Journal of Cancer, 64, 70-75. [Google Scholar] [CrossRef] [PubMed]
[4] Rha, S., Jeung, H., Roh, J., Nishitani, M.-A., Kanda, K., Kanayama, H.-O., et al. (2002) Biological Phenotype Determination with ex Vivo Model in Gastric Cancer for Ma-trix-Metalloproteinase Inhibitor Treatment. International Journal of Molecular Medicine, 10, 251-256. http://www.spandidos-publications.com/10.3892/ijmm.10.3.251 [Google Scholar] [CrossRef] 
[5] Takahashi, M., Oka, N., Naroda, T., Nishitani, M.A., Kanda, K., Kanayama, H.O., et al. (2002) Prognostic Significance of Matrix Metalloproteinases-2 Activation Ratio in Renal Cell Carcinoma. International Journal of Urology, 9, 531-538. [Google Scholar] [CrossRef] [PubMed]
[6] Shah, S.A., Spinale, F.G., Ikonomidis, J.S., Stroud, R.E., Chang, E.I., Reed, C.E., et al. (2010) Differential Matrix Metalloproteinase Levels in Adenocarcinoma and Squamous Cell Carcinoma of the Lung. The Journal of Thoracic and Cardiovascular Surgery, 139, 984-990. [Google Scholar] [CrossRef] [PubMed]
[7] Köhrmann, A., Kammerer, U., Kapp, M., Dietl, J. and Anacker, J. (2009) Expression of Matrix Metalloproteinases (MMPs) in Primary Human Breast Cancer and Breast Cancer Cell Lines: New Findings and Review of the Literature. BMC Cancer, 9, Article No. 188. [Google Scholar] [CrossRef] [PubMed]
[8] Ueda, M., Terai, Y., Yamashita, Y., Kumagai, K., Ueki, K., Yama-guchi, H., et al. (2002) Correlation between Vascular Endothelial Growth Factor-C Expression and Invasion Phenotype in Cervical Carcinomas. International Journal of Cancer, 98, 335-343. [Google Scholar] [CrossRef] [PubMed]
[9] Littlepage, L.E., Sternlicht, M.D., Rougier, N., Phillips, J., Gallo, E., Yu, Y., et al. (2010) Matrix Metalloproteinases Contribute Distinct Roles in Neuroendocrine Prostate Carcinogenesis, Metastasis, and Angiogenesis Progression. Cancer Research, 70, 2224-2234. [Google Scholar] [CrossRef] 
[10] Escaff, S., Fernández, J.M., González, L.O., Suárez, A., González-Reyes, S., González, J.M., et al. (2010) Study of Matrix Metalloproteinases and Their Inhibitors in Prostate Cancer. British Journal of Cancer, 102, 922-929. [Google Scholar] [CrossRef] [PubMed]
[11] Choi, Y.D., Cho, N.H., Ahn, H.S., Cho, K.S., Cho, S.Y. and Yang, W.J. (2007) Matrix Metalloproteinase Expression in the Recurrence of Superficial Low Grade Bladder Transitional Cell Carcinoma. Journal of Urology, 177, 1174-1178. [Google Scholar] [CrossRef] [PubMed]
[12] Aggarwal, B.B., Kumar, A. and Bharti, A.C. (2003) Anticancer Potential of Curcumin: Preclinical and Clinical Studies. Anticancer Research, 23, 363-398.
[13] Hirohashi, S. (1998) Inactivation of the E-Cadherin-Mediated Cell Adhesion System in Human Cancers. The American Journal of Pathology, 153, 333-339. [Google Scholar] [CrossRef] 
[14] Gabison, E.E., Hoang-Xuan, T., Mauviel, A. and Menashi, S. (2005) EMMPRIN/CD147, a MMP Modulator in Cancer, Development and Tissue Repair. Biochimie, 87, 361-368. [Google Scholar] [CrossRef] [PubMed]
[15] Xie, K., Wei, D., Shi, Q. and Huang, S. (2004) Constitutive and Inducible Expression and Regulation of Vascular Endothelial Growth Factor. Cytokine & Growth Factor Reviews, 15, 297-324. [Google Scholar] [CrossRef] [PubMed]
[16] Hoeben, A., Landuyt, B., Highley, M.S., Wildiers, H., Van Oosterom, A.T. and De Bruijn, E.A. (2004) Vascular Endothelial Growth Factor and Angiogenesis. Pharmacological Reviews, 56, 549-580. [Google Scholar] [CrossRef] [PubMed]
[17] Liu, D., Guo, H., Li, Y., Xu, X., Yang, K. and Bai, Y. (2012) Association between Polymorphisms in the Promoter Regions of Matrix Metalloproteinases (MMPs) and Risk of Cancer Metastasis: A Meta-Analysis. PLoS ONE, 7, Article ID: e31251. [Google Scholar] [CrossRef] [PubMed]
[18] Przybylowska, K., Zielinska, J., Zadrozny, M., Krawczyk, T., Kulig, A., Wozniak, P., et al. (2004) An Association between the Matrix Metalloproteinase 1 Promoter Gene Polymor-phism and Lymphnode Metastasis in Breast Cancer. Journal of Experimental & Clinical Cancer Research, 23, 121-125.
[19] Decock, J., Paridaens, R. and Ye, S. (2007) Genetic Polymorphisms of Matrix Metalloproteinases in Lung, Breast and Colorectal Cancer. Clinical Genetics, 73, 197-211. [Google Scholar] [CrossRef] [PubMed]
[20] Illman, S.A., Lehti, K., Keski-Oja, J. and Lohi, J. (2006) Epilysin (MMP-28) Induces TGF-β Mediated Epithelial to Mesenchymal Transition in Lung Carcinoma Cells. Journal of Cell Science, 119, 3856-3865. [Google Scholar] [CrossRef] [PubMed]
[21] Annaházi, A., Ábrahám, S., Farkas, K., Rosztóczy, A., Inczefi, O., Földesi, I., et al. (2016) A Pilot Study on Faecal MMP-9: A New Noninvasive Diagnostic Marker of Colorectal Cancer. British Journal of Cancer, 114, 787-792. [Google Scholar] [CrossRef] [PubMed]
[22] Stott-Miller, M., Houck, J.R., Lohavanichbutr, P., Méndez, E., Upton, M.P., Futran, N.D., et al. (2011) Tumor and Salivary Matrix Metalloproteinase Levels Are Strong Diagnostic Markers of Oral Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers & Prevention, 20, 2628-2636. [Google Scholar] [CrossRef] 
[23] Lee, S., Desai, K.K., Iczkowski, K.A., Newcomer, R.G., Wu, K.J., Zhao, Y.G., et al. (2006) Coordinated Peak Expression of MMP-26 and TIMP-4 in Preinvasive Human Prostate Tumor. Cell Research, 16, 750-758. [Google Scholar] [CrossRef] [PubMed]
[24] Tahara, K., Mimori, K., Iinuma, H., Iwatsuki, M., Yokobori, T., Ishii, H., et al. (2010) Serum Matrix-Metalloproteinase-1 Is a Bona Fide Prognostic Marker for Colorectal Cancer. Annals of Sur-gical Oncology, 17, 3362-3369. [Google Scholar] [CrossRef] [PubMed]
[25] Groblewska, M., Mroczko, B. and Szmitkowski, M. (2010) The Role of Selected Matrix Metalloproteinases and Their Inhibitors in Colorectal Cancer Development. Postepy Higieny I Medycyny Doswiadczalnej, 64, 22-30.
[26] Luukkaa, H., Klemi, P., Hirsimäki, P., Vahlberg, T., Kivisaari, A., Kähäri, V.M., et al. (2010) Matrix Metalloproteinase (MMP)-7 in Salivary Gland Cancer. Acta Oncologica, 49, 85-90. [Google Scholar] [CrossRef] [PubMed]
[27] Stenvold, H., Donnem, T., Andersen, S., Al-Saad, S., Al-Shibli, K., Busund, L.T., et al. (2012) Overexpression of Matrix Metalloproteinase-7 and -9 in NSCLC Tumor and Stromal Cells: Correlation with A Favorable Clinical Outcome. Lung Cancer, 75, 235-241. [Google Scholar] [CrossRef] [PubMed]
[28] Hidalgo, M. and Eckhardt, S.G. (2001) Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy. Journal of the National Cancer Institute, 93, 178-193. [Google Scholar] [CrossRef] [PubMed]

为你推荐